CTX-GLS

Description

Cyclophosphamide is among the older alkylating agents which has stood the test of time. Its proven benefits in a wide variety of cancers, including haematological malignancies, has made it an irreplaceable component of innumerous chemotherapy regimens. Cyclophosphamide is used in both malignant as well as non-malignant disease.

Indications:

Malignant Disease

• For the treatment of Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or duffse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma
• Multiple myeloma
• Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia, (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration)
• Mycosis fungoides (advanced disease)
• Neuroblastoma (disseminated disease)
• Adenocarcinoma of the ovary
• Retinoblastoma
• Carcinoma of the breast

Nonmalignant Disease

• CTX-GLS is useful in carefully selected cases of biopsy proven “minimal change” nephrotic syndrome in children but should not be used as primary therapy
• In children whose disease fails to respond adequately to appropriate adrenocorticosteroid therapy or in whom the adrenocorticosteroid therapy produces or threatens to produce intolerable side effects, cyclophosphamide may induce a remission

Note: Cyclophosphamide is not indicated for the nephrotic syndrome in adults or for any other renal disease.